Compare Starbucks Corp (SBUX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs Zimmer Biomet Holdings Inc — how do they compare? Starbucks Corp trades at $90.87 (market cap $106.26B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Starbucks Corp is far larger — about 6.3× Zimmer Biomet Holdings Inc's market cap, and Starbucks Corp pays the higher dividend (2.7%). Which is the better fit depends on your goals — on Pluang, investors hold Starbucks Corp for 190 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SBUX | ZBH | |
|---|---|---|
Market Cap | $106.26B | $16.95B |
Volume | 30,248,434 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $103.98 |
52-Week Low | $78.46 | $79.58 |
Typical Hold Time | 190 Days | 89 Days |
Enterprise Value | $125.08B | $24.02B |
Dividend Yield | 2.7% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $90.75, down 3.02% today, amid a bearish technical outlook and mixed fundamental performance. The company reported Q2 2026 EPS beat ($0.85 vs. $0.66 expected) but missed in Q4 2025, with revenue growth slowing to 2.8% year-over-year in 2025. Recent news highlights store closures (250 locations) and strategic portfolio reset, while analyst consensus remains positive with a $115.50 price target. Negative shareholder equity and elevated debt levels present financial concerns.
Outlook: Near-term pressure from restructuring and geopolitical risks, but long-term growth potential in high-performing locations and international markets. Risks include execution on store strategy, labor relations, and China exposure. Investment case hinges on successful turnaround and margin recovery.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
